Because the somatic EML4-ALK v3 rearrangement was affirmatively identified in newly acquired biopsy material from a lymph node metastasis using whole genome sequencing, the patient was considered a potential candidate for inclusion in the DRUP trial with ALK as a therapeutic target. Here, EML4 is linked to metastatic malignant neoplasm in the lymph nodes.